COVID-19: Regulatory implications for Europe & Asia in the life sciences & healthcare industry
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and state use/compulsory licensing.
Australia Belgium China Czech Republic Denmark France Finland Germany Hong Kong Hungary Italy Netherlands Poland Singapore Slovakia Spain Sweden UAE United Kingdom
Clinical Trials Medical Devices Public Procurement (All countries) Public Procurement (Europe only) State Use/Compulsory Licensing